Zobrazeno 1 - 10
of 9 872
pro vyhledávání: '"drug‐drug interaction"'
Autor:
Randy E. David, Kelsy Gibson Ferrara, Joshua Schrecker, David Paculdo, Steven Johnson, Rhonda Bentley-Lewis, Rebecca Heltsley, John W. Peabody
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Clinical management of patients with chronic cardiometabolic disease is complicated by polypharmacy. Consequently, when patients clinically deteriorate, physicians are challenged to distinguish both medication nonadherence and dru
Externí odkaz:
https://doaj.org/article/fe40f4cc81ec467da715f599fe3c6ba3
Autor:
Tekletsadik Tekleslassie Alemayehu, Yilkal Abebaw Wassie, Abaynesh Fentahun Bekalu, Addisu Afrassa Tegegne, Wendim Ayenew, Gebresilassie Tadesse, Demis Getachew, Abebaw Setegn Yazie, Bisrat Birke Teketelew, Mekonnen Derese Mekete, Setegn Fentahun, Tesfaye Birhanu Abebe, Tefera Minwagaw, Gebremariam Wulie Geremew
Publikováno v:
Global Health Research and Policy, Vol 9, Iss 1, Pp 1-13 (2024)
Abstract Background The occurrence of potential drug‒drug interactions (pDDIs) is a serious global issue that affects all age groups, with the elderly population being the most vulnerable. This is due to their relatively high rates of comorbidity a
Externí odkaz:
https://doaj.org/article/cf109e5be6f741b6881ce55acd7d9346
Publikováno v:
BMC Chemistry, Vol 18, Iss 1, Pp 1-8 (2024)
Abstract We established a method based on ultra performance liquid chromatography tandem mass spectrometry (UPLC‒MS/MS) to quantitatively measure tepotinib, which was validated as acceptable and used in the evaluation of food-drug interactions betw
Externí odkaz:
https://doaj.org/article/01ac677fb8b84b36ace4047b7ba50bea
Autor:
Junichi Nakagawa, Keinosuke Ishido, Norihisa Kimura, Hayato Nagase, Yusuke Wakasa, Satoshi Yokoyama, Kayo Ueno, Kenichi Hakamada, Takenori Niioka
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-5 (2024)
Abstract Background Edoxaban, the only factor Xa inhibitor with active metabolites, is metabolized by carboxylesterase-1 to its main active metabolite, M-4, which is a substrate of organic anion transporting polypeptide 1B1 (OATP1B1) and is excreted
Externí odkaz:
https://doaj.org/article/808e8076a22f46e093c51c4ca97d3206
Publikováno v:
Journal of Cheminformatics, Vol 16, Iss 1, Pp 1-18 (2024)
Abstract State‑of‑the‑art medical studies proved that predicting CYP450 enzyme inhibitors is beneficial in the early stage of drug discovery. However, accurate machine learning-based (ML) in silico methods for predicting CYP450 inhibitors remai
Externí odkaz:
https://doaj.org/article/12cbfa8efbcd4f1ba8c069e2ebd4a4fa
Autor:
Sandy Van Hemelryck, Erika Van Landuyt, Jay Ariyawansa, Martyn Palmer, Martine J. C. Kothe, Caroline Pollefliet
Publikováno v:
AAPS Open, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Objective Darunavir (DRV) is a P-glycoprotein (P-gp) inhibitor. Dabigatran etexilate, prodrug of the anticoagulant dabigatran, is a P-gp probe substrate. This study evaluated the effect of single and multiple doses of DRV, coadministered wit
Externí odkaz:
https://doaj.org/article/8f9ffe32fdc24ef8bc61f8b1a1066bf2
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Combining immune checkpoint and proton pump inhibitors is widely used in cancer treatment. However, the drug-drug interactions of these substances are currently unknown. This study aimed to explore drug-drug interactions associate
Externí odkaz:
https://doaj.org/article/5fe85e835f69445692ad453ca97b9064
Autor:
Rina Matsuoka, Shinsuke Akagi, Tomohiro Konishi, Masashi Kondo, Hideki Matsubara, Shohei Yamamoto, Keiji Izushi, Yuichi Tasaka
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Background Drug-drug interactions (DDIs) increase the incidence of adverse drug reactions (ADRs). In a previous report, we revealed that the incidence of potential DDIs due to the same CYP molecular species in one prescription exceeds 90% am
Externí odkaz:
https://doaj.org/article/041504f2fb574a8d904f7826fa719a5b
Autor:
Toshinori Hirai, Shun Ueda, Toru Ogura, Kan Katayama, Kaoru Dohi, Yuki Kondo, Yuka Sakazaki, Yoichi Ishitsuka, Takuya Iwamoto
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Background We examined whether the pharmacodynamic drug–drug interaction between esaxerenone and trimethoprim enhances the hyperkalemic effect. Methods A retrospective observational study was conducted to identify patients >18 years undert
Externí odkaz:
https://doaj.org/article/d2c33a06609e45938fdce40f0c68b926
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 3113-3119 (2024)
Jin Wang, Chaoying Hu, Lan Zhang Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Chaoying Hu; Lan Zhang, Email hucarol@126.com; xwzhanglan@126.com
Externí odkaz:
https://doaj.org/article/0e1c37c7b91a44baa1749cf2d47ee5a2